Outlook Therapeutics (OTLK) Return on Equity: 2016-2020
Historic Return on Equity for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to 8.05%.
- Outlook Therapeutics' Return on Equity rose 594.00% to 8.05% in Q2 2020 from the same period last year, while for Jun 2020 it was 8.05%, marking a year-over-year increase of 594.00%. This contributed to the annual value of 1.66% for FY2019, which is 64.00% up from last year.
- Outlook Therapeutics' Return on Equity amounted to 8.05% in Q2 2020, which was up 419.07% from 1.55% recorded in Q1 2020.
- Outlook Therapeutics' Return on Equity's 5-year high stood at 29.53% during Q3 2016, with a 5-year trough of 0.72% in Q1 2018.
- Moreover, its 3-year median value for Return on Equity was 1.52% (2019), whereas its average is 2.25%.
- Its Return on Equity has fluctuated over the past 5 years, first tumbled by 2,829bps in 2017, then skyrocketed by 594bps in 2020.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Return on Equity stood at 4.11% in 2016, then plummeted by 338bps to 0.74% in 2017, then skyrocketed by 72bps to 1.46% in 2018, then decreased by 3bps to 1.43% in 2019, then skyrocketed by 594bps to 8.05% in 2020.
- Its Return on Equity stands at 8.05% for Q2 2020, versus 1.55% for Q1 2020 and 1.43% for Q4 2019.